Summary Ten adult male patients with long‐standing atopic eczema took part in a double‐blind randomized cross‐over trial of compound LN2974. This is a new potent selective H1‐receptor antagonist, unrelated to other antihistamines and devoid of H2‐reccptor antagonist activity. It has little or no sedative action. No significant suppression of scratching, as measured by limb movement meters, or of itching, recorded on visual analogue scales, could be demonstrated.

No abstract